<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TAZORAC
- tazarotene
Â creamÂ </strong><br>Allergan, Inc.
<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use TAZORAC<span class="Sup">Â®</span> Cream safely and effectively.  See full prescribing information for TAZORAC<span class="Sup">Â®</span> Cream.<br>TAZORAC<span class="Sup">Â®</span> (tazarotene) cream, 0.05% and 0.1%, for topical use<br>Initial U.S. Approval: 1997
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul class="Disc">
<li>TAZORAC<span class="Sup">Â®</span> Cream 0.05% and 0.1% is a retinoid indicated for the topical treatment of plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>. (<a href="#s2">1.1</a>)
</li>
<li>TAZORAC<span class="Sup">Â®</span> Cream 0.1% is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>. (<a href="#s3">1.2</a>)
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Apply a thin layer of TAZORAC<span class="Sup">Â®</span> Cream only to the affected area once daily in the evening. (<a href="#s5">2.1</a>, <a href="#s6">2.2</a>)
</li>
<li>Not for ophthalmic, oral, or intravaginal use. (<a href="#s6">2.2</a>)
</li>
<li>If contact with eyes occurs, rinse thoroughly with water. (<a href="#s6">2.2</a>)
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Cream, 0.05% and 0.1%. (<a href="#s7">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy (<a href="#s9">4.1</a>, <a href="#s21">8.1</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<a href="#s10">4.2</a>)
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Embryofetal Toxicity: TAZORAC<span class="Sup">Â®</span> Cream contains tazarotene, which is a teratogenic substance. TAZORAC<span class="Sup">Â®</span> Cream is contraindicated in pregnancy. Females of child-bearing potential should have a <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span> within 2 weeks prior to initiating treatment and use an effective method of contraception during treatment. (<a href="#s12">5.1</a>)
</li>
<li>Local Irritation: Some individuals may experience excessive <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, burning, skin <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>. If these effects occur, discontinue until the integrity of the skin has been restored, or reduce dosing interval, or in the case of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, may switch to the lower concentration. TAZORAC<span class="Sup">Â®</span> Cream should not be used on eczematous skin, as it may cause severe irritation. (<a href="#s13">5.2</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> and Risk for Sunburn: Avoid exposure to sunlight, sunlamps, and weather extremes. Wear sunscreen daily. TAZORAC<span class="Sup">Â®</span> Cream should be administered with caution if the patient is also taking drugs known to be photosensitizers. (<a href="#s14">5.3</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc">
<li>Plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>: Most common adverse reactions occurring in 10 to 23% of patients are <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and burning. (<a href="#s16">6.1</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne Vulgaris</span>: Most common adverse reactions occurring in 10 to 30% of patients are <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>. (<a href="#s16">6.1</a>)
</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Allergan, Inc. at 1-800-433-8871 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 12/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h2><a href="#section-1.1" class="toc">1.1  Plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span>
</a></h2>
<h2><a href="#section-1.2" class="toc">1.2  <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne Vulgaris</span>
</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1  <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span>
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2  <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h2><a href="#section-4.1" class="toc">4.1  Pregnancy
</a></h2>
<h2><a href="#section-4.2" class="toc">4.2  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  Embryofetal Toxicity
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Local Irritation
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3  <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> and Risk for Sunburn
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1   Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.3   Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">8.4   Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">8.5   Geriatric Use
</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.2  Pharmacodynamics
</a></h2>
<h2><a href="#section-11.3" class="toc">12.3  Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES
</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s2"></a><a name="section-1.1"></a><p></p>
<h2>1.1  Plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span>
</h2>
<p class="First">TAZORAC<span class="Sup">Â®</span> (tazarotene) Cream, 0.05% and 0.1% are indicated for the topical treatment of patients with plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-1.2"></a><p></p>
<h2>1.2  <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne Vulgaris</span>
</h2>
<p class="First">TAZORAC<span class="Sup">Â®</span> (tazarotene) Cream, 0.1% is also indicated for the topical treatment of patients with <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s4"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.1"></a><p></p>
<h2>2.1  <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span>
</h2>
<p class="First">It is recommended that treatment starts with TAZORAC<span class="Sup">Â®</span> Cream, 0.05%, with strength increased to 0.1% if tolerated and medically indicated. Apply a thin film (2 mg/cm<span class="Sup">2</span>) of TAZORAC<span class="Sup">Â®</span> Cream once per day, in the evening, to cover only the psoriatic lesions. If a bath or shower is taken prior to application, the skin should be dry before applying the cream. If emollients are used, they should be applied at least an hour before application of TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream. Because unaffected skin may be more susceptible to irritation, application of TAZORAC<span class="Sup">Â®</span> Cream to these areas should be carefully avoided.<br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.2"></a><p></p>
<h2>2.2  <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>
</h2>
<p class="First">Cleanse the face gently. After the skin is dry, apply a thin layer (2 mg/cm<span class="Sup">2</span>) of TAZORAC<span class="Sup">Â®</span> Cream 0.1% once per day, in the evening, to the skin areas where <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> lesions appear. Use enough to cover the entire affected area.
</p>
<p>TAZORAC<span class="Sup">Â®</span> Cream is for topical use only. TAZORAC<span class="Sup">Â®</span> Cream is not for ophthalmic, oral, or intravaginal use. If contact with eyes occurs, rinse thoroughly with water.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s7"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Cream, 0.05% and 0.1%. Each gram of TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.05% and 0.1% contains 0.5 mg and 1 mg of tazarotene, respectively in a white cream base.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s8"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-4.1"></a><p></p>
<h2>4.1  Pregnancy
</h2>
<p class="First">TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream may cause fetal harm when administered to a pregnant woman. Tazarotene elicits teratogenic and developmental effects associated with retinoids after topical or systemic administration in rats and rabbits <span class="Italics">[see Use in Specific Populations (<a href="#s21">8.1</a>)]</span>. TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream is contraindicated in women who are pregnant or may become pregnant.
</p>
<p>If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, treatment should be discontinued and the patient should be apprised of the potential hazard to the fetus <span class="Italics">[see Warnings and Precautions (<a href="#s12">5.1</a>) and Use in Specific Populations (<a href="#s21">8.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-4.2"></a><p></p>
<h2>4.2  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</h2>
<p class="First">TAZORAC<span class="Sup">Â®</span> Cream is contraindicated in individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s11"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-5.1"></a><p></p>
<h2>5.1  Embryofetal Toxicity
</h2>
<p class="First">Systemic exposure to tazarotenic acid is dependent upon the extent of the body surface area treated. In patients treated topically over sufficient body surface area, exposure could be in the same order of magnitude as in orally treated animals.  Although there may be less systemic exposure in the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> of the face alone due to less surface area for application, tazarotene is a teratogenic substance, and it is not known what level of exposure is required for <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in humans <span class="Italics">[see Clinical Pharmacology (<a href="#s30">12.3</a>)]</span>.
</p>
<p>There were thirteen reported pregnancies in subjects who participated in the clinical trials for topical tazarotene. Nine of the subjects were found to have been treated with topical tazarotene, and the other four had been treated with vehicle. One of the subjects who was treated with tazarotene cream elected to terminate the pregnancy for non-medical reasons unrelated to treatment. The other eight pregnant women who were inadvertently exposed to topical tazarotene during clinical trials subsequently delivered apparently healthy babies. As the exact timing and extent of exposure in relation to the gestation times are not certain, the significance of these findings is unknown.
</p>
<p><span class="Italics">Females of Child-bearing Potential</span></p>
<p>Females of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when TAZORAC<span class="Sup">Â®</span> Cream is used. The possibility that a female of child-bearing potential is pregnant at the time of institution of therapy should be considered.
</p>
<p>A negative result for pregnancy test should be obtained within 2 weeks prior to TAZORAC<span class="Sup">Â®</span> Cream therapy. TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream therapy should begin during a menstrual period <span class="Italics">[see Use in Specific Populations (<a href="#s21">8.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Local Irritation
</h2>
<p class="First">Application of TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream may cause excessive irritation in the skin of certain sensitive individuals. Some individuals may experience excessive <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, burning, skin <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the dosing should be reduced to an interval the patient can tolerate. However, efficacy at reduced frequency of application has not been established. Alternatively, patients with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> who are being treated with the 0.1% concentration can be switched to the lower concentration. Frequency of application should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance. Therapy can be resumed, or the drug concentration or frequency of application can be increased as the patient becomes able to tolerate treatment.
</p>
<p>Concomitant topical medications and cosmetics that have a strong drying effect should be avoided. It is also advisable to "rest" a patient's skin until the effects of such preparations subside before use of TAZORAC<span class="Sup">Â®</span> Cream is begun.
</p>
<p>TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, should not be used on eczematous skin, as it may cause severe irritation.
</p>
<p>Weather extremes, such as <span class="product-label-link" type="condition" conceptid="4221803" conceptname="Flatus">wind</span> or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, may be more irritating to patients using TAZORAC<span class="Sup">Â®</span> Cream.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-5.3"></a><p></p>
<h2>5.3  <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> and Risk for Sunburn
</h2>
<p class="First">Because of heightened burning susceptibility, exposure to sunlight (including sunlamps) should be avoided unless deemed medically necessary, and in such cases, exposure should be minimized during the use of TAZORAC<span class="Sup">Â®</span> Cream. Patients must be warned to use sunscreens (minimum SPF of 15) and protective clothing when using TAZORAC<span class="Sup">Â®</span> Cream. Patients with sunburn should be advised not to use TAZORAC<span class="Sup">Â®</span> Cream until fully recovered. Patients who may have considerable sun exposure due to their occupation and those patients with inherent sensitivity to sunlight should exercise particular caution when using TAZORAC<span class="Sup">Â®</span> Cream.
</p>
<p>TAZORAC<span class="Sup">Â®</span> Cream should be administered with caution if the patient is also taking drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the increased possibility of augmented <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s15"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
</p>
<p>In human dermal safety trials, TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.05% and 0.1% did not induce allergic contact sensitization, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span>, or photoallergy.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span></span></p>
<p>The most frequent adverse reactions reported with TAZORAC<span class="Sup">Â®</span> Cream, 0.05% and 0.1% occurring in 10 to 23% of subjects, in descending order, included <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and burning. Reactions occurring in greater than 1 to less than 10% of subjects, in descending order, included irritation, <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, worsening of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, skin <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">skin inflammation</span>, and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>.
</p>
<p>TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.1% was associated with a greater degree of local irritation than the 0.05% cream. The rates of irritation adverse reactions reported during <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> trials with TAZORAC<span class="Sup">Â®</span> Cream, 0.1% were 0.1-0.4% higher than those reported for TAZORAC<span class="Sup">Â®</span> Cream, 0.05%.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></span></p>
<p>The most frequent adverse reactions reported during clinical trials with TAZORAC<span class="Sup">Â®</span> Cream 0.1% in the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, occurring in 10-30% of subjects, in descending order included <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>. Reactions occurring in 1 to 5% of subjects included <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, irritation, face <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s19"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<p class="First">No formal drug-drug interaction studies were conducted with TAZORAC<span class="Sup">Â®</span> Cream.
</p>
<p>In a trial of 27 healthy female subjects between the ages of 20â€“55 years receiving a combination oral contraceptive tablet containing 1 mg norethindrone and 35 mcg ethinyl estradiol, concomitant use of tazarotene administered as 1.1 mg orally (mean Â± SD C<span class="Sub">max</span> and AUC<span class="Sub">0-24</span> of tazarotenic acid were 28.9 Â± 9.4 ng/mL and 120.6 Â± 28.5 ngâˆ™hr/mL) did not affect the pharmacokinetics of norethindrone and ethinyl estradiol over a complete cycle.
</p>
<p>The impact of tazarotene on the pharmacokinetics of progestin only oral contraceptives (i.e., minipills) has not been evaluated.
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s20"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s21"></a><a name="section-8.1"></a><p></p>
<h2>8.1   Pregnancy
</h2>
<p class="First">Pregnancy Category X <span class="Italics">[see Contraindications (<a href="#s9">4.1</a>)]</span>.
</p>
<p>There are no adequate and well-controlled studies with TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream in pregnant women. TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream is contraindicated in women who are or may become pregnant. Females of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when TAZORAC<span class="Sup">Â®</span> Cream is used. The possibility that a female of child-bearing potential is pregnant at the time of institution of therapy should be considered. A negative result for pregnancy test should be obtained within 2 weeks prior to TAZORAC<span class="Sup">Â®</span> Cream therapy, which should begin during a menstrual period. Systemic exposure to tazarotenic acid is dependent upon the extent of the body surface area treated. In subjects treated topically over sufficient body surface area, exposure could be in the same order of magnitude as in orally treated animals. Although there may be less systemic exposure in the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> of the face alone due to less surface area for application, tazarotene is a teratogenic substance, and it is not known what level of exposure is required for <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in humans <span class="Italics">[see Clinical Pharmacology (<a href="#s30">12.3</a>)]</span>.
</p>
<p>In rats, a tazarotene gel, 0.05% formulation, administered topically during gestation days 6 through 17 at 0.25Â mg/kg/day resulted in reduced fetal body weights and reduced skeletal ossification. Rabbits dosed topically with 0.25 mg/kg/day tazarotene gel during gestation days 6 through 18 were noted with single incidences of known retinoid malformations, including <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span>, <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephaly</span>, and heart anomalies.
</p>
<p>Systemic exposure to tazarotenic acid at topical doses of 0.25 mg/kg/day tazarotene in a gel formulation in rats and rabbits represented 1.2 and 13 times, respectively, that in a psoriatic patient treated with 0.1% tazarotene cream at 2 mg/cm<span class="Sup">2</span> over a 35% body surface area in a controlled pharmacokinetic study, and 4 and 44 times the maximum systemic exposure in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with tazarotene cream, 0.1% at 2 mg/cm<span class="Sup">2</span> over a 15% body surface area.
</p>
<p>When tazarotene was given orally to experimental animals, <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span> were seen in rats; and teratogenic effects and post-implantation loss were observed in rats and rabbits at doses producing 1.1 and 26 times, respectively, the systemic exposure seen in a psoriatic patient treated topically with tazarotene cream, 0.1% at 2 mg/cm<span class="Sup">2</span> over a 35% body surface area in a controlled pharmacokinetic study and 3.5 and 85 times the maximum systemic exposure  in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with tazarotene cream, 0.1% at 2 mg/cm<span class="Sup">2</span> over a 15% body surface area.
</p>
<p>In female rats orally administered 2 mg/kg/day of tazarotene from 15 days before mating through gestation day 7, a number of classic developmental effects of retinoids were observed including decreased number of implantation sites, decreased litter size, decreased numbers of live fetuses, and decreased fetal body weights. A low incidence of retinoid-related malformations at that dose was observed. The dose produced a systemic exposure 3.4 times that observed in a psoriatic patient treated with tazarotene cream, 0.1% at 2 mg/cm<span class="Sup">2</span> over a 35% body surface area and 11 times the maximum systemic exposure in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with tazarotene cream, 0.1% at 2 mg/cm<span class="Sup">2</span> over a 15% body surface area.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s22"></a><a name="section-8.2"></a><p></p>
<h2>8.3   Nursing Mothers
</h2>
<p class="First">After single topical doses of <span class="Sup">14</span>C-tazarotene gel to the skin of lactating rats, radioactivity was detected in milk, suggesting that there would be transfer of drug-related material to the offspring via milk. It is not known whether this drug is excreted in human milk. The safe use of TAZORAC<span class="Sup">Â®</span> Cream during lactation has not been established. A decision should be made whether to discontinue breast-feeding or to discontinue TAZORAC<span class="Sup">Â®</span> Cream therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s23"></a><a name="section-8.3"></a><p></p>
<h2>8.4   Pediatric Use
</h2>
<p class="First">The safety and efficacy of tazarotene have not been established in patients with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> under the age of 18 years, or in patients with <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> under the age of 12 years.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s24"></a><a name="section-8.4"></a><p></p>
<h2>8.5   Geriatric Use
</h2>
<p class="First">TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream for the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> has not been clinically tested in persons 65 years of age or older.
</p>
<p>Of the total number of subjects in clinical trials of TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream for plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, 120 were over the age of 65. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Currently there is no other clinical experience on the differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s25"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<p class="First">Excessive topical use of TAZORAC<span class="Sup">Â®</span> Cream, 0.05% and 0.1% may lead to marked <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> <span class="Italics">[see Warnings and Precautions (<a href="#s13">5.2</a>)]</span>.
</p>
<p>TAZORAC<span class="Sup">Â®</span> Cream, 0.05% and 0.1% are not for oral use. Oral ingestion of the drug may lead to the same adverse effects as those associated with excessive oral intake of Vitamin A (<span class="product-label-link" type="condition" conceptid="436941" conceptname="Hypervitaminosis A">hypervitaminosis A</span>) or other retinoids. If oral ingestion occurs, the patient should be monitored, and appropriate supportive measures should be administered as necessary.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s26"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">TAZORAC<span class="Sup">Â®</span> (tazarotene) Cream, 0.05% and 0.1% is for topical use and contains the active ingredient, tazarotene.  Each gram of TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.05% and 0.1% contains 0.5 and 1 mg of tazarotene, respectively in a white cream base.
</p>
<p>Tazarotene is a member of the acetylenic class of retinoids. Chemically, tazarotene is ethyl 6-[(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate.  The compound has an empirical formula of C<span class="Sub">21</span>H<span class="Sub">21</span>NO<span class="Sub">2</span>S and molecular weight of 351.46.  The structural formula is shown below:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd02ea43-7668-4872-a655-ee31c456e345&amp;name=structuralformula.jpg">
</div>
<p>TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream contains the following inactive ingredients: benzyl alcohol 1%; carbomer 1342; carbomer homopolymer type B; edetate disodium; medium chain triglycerides; mineral oil; purified water; sodium hydroxide; sodium thiosulfate; and sorbitan monooleate.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s27"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s28"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action
</h2>
<p class="First">Tazarotene is a retinoid prodrug which is converted to its active form, the carboxylic acid of tazarotene, by deesterification. Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family: RARÎ±<span class="Sub">,</span> RARÎ², and RARÎ³, but shows relative selectivity for RARÎ², and RARÎ³ and may modify gene expression. The clinical significance of these findings is unknown.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s29"></a><a name="section-11.2"></a><p></p>
<h2>12.2  Pharmacodynamics
</h2>
<p class="First">The pharmacodynamics of TAZORAC<span class="Sup">Â®</span> Cream are unknown.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s30"></a><a name="section-11.3"></a><p></p>
<h2>12.3  Pharmacokinetics
</h2>
<p class="First">Following topical application, tazarotene undergoes esterase hydrolysis to form its active metabolite, tazarotenic acid. Little parent compound could be detected in the plasma. Tazarotenic acid was highly bound to plasma proteins (greater than 99%). Tazarotene and tazarotenic acid were metabolized to sulfoxides, sulfones and other polar metabolites which were eliminated through urinary and fecal pathways. The half-life of tazarotenic acid was approximately 18Â hours, following topical application of tazarotene to normal, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> or psoriatic skin.
</p>
<p>In a multiple dose trial with a once daily dose for 14 consecutive days in 9 psoriatic subjects (male=5; female=4), measured doses of TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.1% were applied by medical staff to involved skin without occlusion (5 to 35% of total body surface area: mean Â± SD: 14 Â± 11%). The C<span class="Sub">max</span> of tazarotenic acid was 2.31 Â± 2.78 ng/mL occurring 8 hours after the final dose, and the AUC<span class="Sub">0-24h</span> was 31.2 Â± 35.2 ngâˆ™hr/mL on day 15 in the five subjects who were administered clinical doses of 2 mg cream/cm<span class="Sup">2</span>.
</p>
<p>During clinical trials with TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.05% or 0.1% treatment for plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, three out of 139 subjects with their systemic exposure monitored had detectable plasma tazarotene concentrations, with the highest value at 0.09Â ng/mL. Tazarotenic acid was detected in 78 out of 139 subjects (LLOQ = 0.05 ng/mL). Three subjects using tazarotene cream 0.1% had plasma tazarotenic acid concentrations greater than 1Â ng/mL. The highest value was 2.4 ng/mL. However, because of the variations in the time of blood sampling, the area of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> involvement, and the dose of tazarotene applied, actual maximal plasma levels are unknown.
</p>
<p>TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream 0.1% was applied once daily to either the face (N=8) or to 15% of body surface area (N=10) of female subjects with moderate to severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>. The mean C<span class="Sub">max</span> and AUC values of tazarotenic acid peaked at day 15 for both dosing groups during a 29 day treatment period. Mean C<span class="Sub">max</span> and AUC<span class="Sub">0-24h</span> values of tazarotenic acid from subjects in the 15% body surface area dosing group were more than 10 times higher than those from subjects in the face-only dosing group. The single highest C<span class="Sub">max</span> throughout the trial period was 1.91 ng/mL on day 15 in the exaggerated dosing group. In the face-only group, the mean Â± SD values of C<span class="Sub">max</span> and AUC<span class="Sub">0-24h</span> of tazarotenic acid on day 15 were 0.10 Â± 0.06 ng/mL and 1.54 Â± 1.01 ngâˆ™hr/mL, respectively, whereas in the 15% body surface area dosing group, the mean Â± SD values of C<span class="Sub">max</span> and AUC<span class="Sub">0-24h</span> of tazarotenic acid on day 15 were 1.20 Â± 0.41 ng/mL and 17.01 Â± 6.15 ngâˆ™hr/mL, respectively. The steady state pharmacokinetics of tazarotenic acid had been reached by day 8 in the face-only and by day 15 in the 15% body surface area dosing groups.
</p>
<p>In a Phase 3 clinical trial, TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.1% was applied once daily for 12 weeks to each of 48 subjects (22 females and 26 males) with facial <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>. The mean Â± SD values of plasma tazarotenic acid at weeks 4 and 8 were 0.078 Â± 0.073 ng/mL (N=47) and 0.052 Â± 0.037 ng/mL (N=42), respectively. The highest observed individual plasma tazarotenic acid concentration was 0.41 ng/mL at week 4 from a female subject. The magnitude of plasma tazarotenic acid concentrations appears to be independent of gender, age, and body weight.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s31"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s32"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Italics">Carcinogenesis</span></p>
<p>A long-term study of tazarotene following oral administration of 0.025, 0.050, and  0.125Â mg/kg/day to rats showed no indications of increased carcinogenic risks. Based on pharmacokinetic data from a shorter term study in rats, the highest dose of 0.125 mg/kg/day was anticipated to give systemic exposure in the rat equivalent to 0.6 times that seen in a psoriatic patient treated with 0.1% tazarotene cream at 2 mg/kg/cm<span class="Sup">2</span> over a 35% body surface area in a controlled pharmacokinetic study. This estimated systemic exposure in rats was 2 times the maximum systemic exposure in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with tazarotene cream, 0.1% cream at 2 mg/cm<span class="Sup">2</span> over a 15% body surface area.
</p>
<p>A long-term topical application study of up to 0.1% of tazarotene in a gel formulation in mice terminated at 88 weeks showed that dose levels of 0.05, 0.125, 0.25, and 1 mg/kg/day (reduced to 0.5 mg/kg/day for males after 41 weeks due to severe dermal irritation) revealed no apparent carcinogenic effects when compared to vehicle control animals. Systemic exposures at the highest dose was 3.9 times that seen in a psoriatic patient treated with 0.1% tazarotene cream at 2 mg/cm<span class="Sup">2</span> over a 35% body surface area in a controlled pharmacokinetic study, and 13 times the maximum systemic exposure in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with tazarotene cream, 0.1% at 2 mg/cm<span class="Sup">2</span> over a 15% body surface area.
</p>
<p>In evaluation of photo co-carcinogenicity, median time to onset of tumors was decreased, and the number of tumors increased in hairless mice following chronic topical dosing with intercurrent exposure to ultraviolet radiation at tazarotene concentrations of 0.001%, 0.005%, and 0.01% in a gel formulation for up to 40 weeks.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Italics">Mutagenesis</span></p>
<p>Tazarotene was found to be non-mutagenic in the Ames assay and did not produce structural chromosomal aberrations in a human lymphocyte assay. Tazarotene was non-mutagenic in the CHO/HGPRT mammalian cell forward gene mutation assay and was non-clastogenic in the <span class="Italics">in vivo</span> mouse micronucleus test.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-12.1.3"></a><p></p>
<p class="First"><span class="Italics">Impairment of Fertility</span></p>
<p>No impairment of fertility occurred in rats when male animals were treated for 70 days prior to mating and female animals were treated for 14Â days prior to mating and continuing through gestation and lactation with topical doses of tazarotene gel up to 0.125Â mg/kg/day. Based on data from another study, the systemic drug exposure in the rat would be equivalent to 0.6 times that observed in a psoriatic patient treated with 0.1% tazarotene cream at 2 mg/cm<span class="Sup">2</span> over a 35% body surface area in a controlled pharmacokinetic study, and 2 times the maximum systemic exposure in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with tazarotene cream, 0.1% at 2 mg/cm<span class="Sup">2</span> over a 15% body surface area.
</p>
<p>No impairment of mating performance or fertility was observed in male rats treated for 70 days prior to mating with oral doses of up to 1 mg/kg/day tazarotene. That dose produced a systemic exposure that was 1.9 times that observed in a psoriatic patient treated with 0.1% tazarotene cream at 2Â mg/cm<span class="Sup">2</span> over a 35% body surface area, and 6.3 times the maximum systemic exposure in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with tazarotene cream, 0.1% at 2 mg/cm<span class="Sup">2</span> over a 15% body surface area.
</p>
<p>No impairment of mating performance or fertility was observed in female rats treated for 15 days prior to mating and continuing through gestation day 7 with oral doses up to 2 mg/kg/day of tazarotene. However, there was a significant decrease in the number of estrous stages and an increase in developmental effects at that dose <span class="Italics">[see Use in Specific Populations (<a href="#s21">8.1</a>)]</span>. That dose produced a systemic exposure that was 3.4 times that observed in a psoriatic patient treated with 0.1% tazarotene cream at 2 mg/cm<span class="Sup">2</span> over a 35% body surface area and 11 times the maximum systemic exposure in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with tazarotene cream, 0.1% at 2 mg/cm<span class="Sup">2</span> over a 15% body surface area.
</p>
<p>Reproductive capabilities of F1 animals, including F2 survival and development, were not affected by topical administration of tazarotene gel to female F0 parental rats from gestation day 16 through lactation day 20 at the maximum tolerated dose of 0.125Â mg/kg/day. Based on data from another study, the systemic drug exposure in the rat would be equivalent to 0.6 times that observed in a psoriatic patient treated with 0.1% tazarotene cream at 2 mg/cm<span class="Sup">2</span> over a 35% body surface area, and 2 times the maximum systemic exposure in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with tazarotene cream, 0.1% at 2Â mg/cm<span class="Sup">2</span> over a 15% body surface area.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s36"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<p class="First">In two 12-week vehicle-controlled clinical trials, TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.05% and 0.1% was significantly more effective than vehicle in reducing the severity of stable plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>. TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.1% and 0.05% demonstrated superiority over vehicle cream as early as 1 week and 2 weeks, respectively, after starting treatment.
</p>
<p>In these trials, the primary efficacy endpoint was â€œclinical success,â€? defined as the proportion of subjects with none, minimal, or mild overall lesional assessment at Week 12, and shown in <a href="#t1">Table 1</a>. â€œClinical successâ€? was also significantly greater with TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.05% and 0.1% versus vehicle at most follow-up visits.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1. Subject Numbers and Percentages for Overall Lesional Assessment Scores and â€œClinical Successâ€? at Baseline (BL), End of Treatment (Week 12) and 12 Weeks After Stopping Therapy (Week 24)<span class="Sup">#</span> in Two Controlled Clinical Trials for <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span>
</span></caption>
<col align="left" width="8.082%">
<col align="left" width="5.825%">
<col align="left" width="6.400%">
<col align="left" width="6.400%">
<col align="left" width="5.825%">
<col align="left" width="6.525%">
<col align="left" width="5.825%">
<col align="left" width="6.550%">
<col align="left" width="6.400%">
<col align="left" width="5.825%">
<col align="left" width="6.400%">
<col align="left" width="5.825%">
<col align="left" width="5.825%">
<col align="left" width="6.232%">
<col align="left" width="5.825%">
<col align="left" width="6.232%">
<tfoot>
<tr class="First"><td align="left" colspan="16" valign="top"><p class="First Footnote">0 no plaque elevation above normal skin level; may have residual non-erythematous discoloration; no psoriatic scale
</p></td></tr>
<tr><td align="left" colspan="16" valign="top"><p class="First Footnote">1 essentially flat with possible trace elevation; may have up to moderate <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (red coloration); no psoriatic scale
</p></td></tr>
<tr><td align="left" colspan="16" valign="top"><p class="First Footnote">2 slight but definite elevation of plaque above normal skin level; may have up to moderate <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (red coloration); fine scales with some lesions partially covered
</p></td></tr>
<tr><td align="left" colspan="16" valign="top"><p class="First Footnote">3 moderate elevation with rounded or sloped edges to plaque; moderate <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (red coloration); somewhat coarser scales with most lesions partially covered
</p></td></tr>
<tr><td align="left" colspan="16" valign="top"><p class="First Footnote">4 marked elevation with hard, sharp edges to plaque; severe <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (very red coloration); thick scales with virtually all lesions covered and a rough surface
</p></td></tr>
<tr class="Last"><td align="left" colspan="16" valign="top"><p class="First Footnote">5 very marked elevation with very hard, sharp edges to plaque; very severe <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (extreme red coloration); very coarse, thick scales with all lesions covered and a very rough surface<br>Clinical Success defined as an overall lesional assessment score of none, minimal, or mild.<br><span class="Bold"># Trial 1 had post-treatment period observations for 12 weeks after stopping therapy, which were not part of Trial 2.<br></span>* <span class="Bold">Denotes statistically significant difference for â€œClinical Successâ€? compared with vehicle.</span></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="left" colspan="5" valign="top">TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.05%
</td>
<td class="Botrule Rrule Toprule" align="left" colspan="5" valign="top">TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.1%
</td>
<td class="Botrule Rrule Toprule" align="left" colspan="5" valign="top">Vehicle Cream
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" colspan="3" valign="top">
<span class="Bold">Trial 1</span><br>N=218
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">
<span class="Bold">Trial 2</span><br>N=210
</td>
<td class="Botrule Rrule" align="left" colspan="3" valign="top">
<span class="Bold">Trial 1</span><br>N=221
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">
<span class="Bold">Trial 2</span><br>N=211
</td>
<td class="Botrule Rrule" align="left" colspan="3" valign="top">
<span class="Bold">Trial 1</span><br>N=229
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">
<span class="Bold">Trial 2</span><br>N=214
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Score
</td>
<td class="Botrule Rrule" align="left" valign="top">BL
</td>
<td class="Botrule Rrule" align="left" valign="top">Wk 12
</td>
<td class="Botrule Rrule" align="left" valign="top">Wk 24
</td>
<td class="Botrule Rrule" align="left" valign="top">BL
</td>
<td class="Botrule Rrule" align="left" valign="top">Wk 12
</td>
<td class="Botrule Rrule" align="left" valign="top">BL
</td>
<td class="Botrule Rrule" align="left" valign="top">Wk 12
</td>
<td class="Botrule Rrule" align="left" valign="top">Wk 24
</td>
<td class="Botrule Rrule" align="left" valign="top">BL
</td>
<td class="Botrule Rrule" align="left" valign="top">Wk 12
</td>
<td class="Botrule Rrule" align="left" valign="top">BL
</td>
<td class="Botrule Rrule" align="left" valign="top">Wk 12
</td>
<td class="Botrule Rrule" align="left" valign="top">Wk 24
</td>
<td class="Botrule Rrule" align="left" valign="top">BL
</td>
<td class="Botrule Rrule" align="left" valign="top">Wk 12
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">None (0)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1<br>(0.5%)
</td>
<td class="Botrule Rrule" align="center" valign="top">1<br>(0.5%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2<br>(1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">6<br>(3%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1<br>(0.4%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1<br>(0.5%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Minimal (1)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">11<br>(5%)
</td>
<td class="Botrule Rrule" align="center" valign="top">12<br>(6%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">7<br>(3%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">12<br>(5%)
</td>
<td class="Botrule Rrule" align="center" valign="top">14<br>(6%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">11<br>(5%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">7<br>(3%)
</td>
<td class="Botrule Rrule" align="center" valign="top">6<br>(3%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1<br>(0.5%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Mild<br>(2)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">79<br>(36%)
</td>
<td class="Botrule Rrule" align="center" valign="top">60<br>(28%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">76<br>(36%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">75<br>(34%)
</td>
<td class="Botrule Rrule" align="center" valign="top">53<br>(24%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">90<br>(43%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">49<br>(21%)
</td>
<td class="Botrule Rrule" align="center" valign="top">43<br>(19%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">54<br>(25%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Moderate (3)
</td>
<td class="Botrule Rrule" align="center" valign="top">141<br>(65%)
</td>
<td class="Botrule Rrule" align="center" valign="top">86<br>(39%)
</td>
<td class="Botrule Rrule" align="center" valign="top">90<br>(41%)
</td>
<td class="Botrule Rrule" align="center" valign="top">100<br>(48%)
</td>
<td class="Botrule Rrule" align="center" valign="top">74<br>(35%)
</td>
<td class="Botrule Rrule" align="center" valign="top">122<br>(55%)
</td>
<td class="Botrule Rrule" align="center" valign="top">97<br>(44%)
</td>
<td class="Botrule Rrule" align="center" valign="top">107<br>(48%)
</td>
<td class="Botrule Rrule" align="center" valign="top">96<br>(45%)
</td>
<td class="Botrule Rrule" align="center" valign="top">62<br>(29%)
</td>
<td class="Botrule Rrule" align="center" valign="top">139<br>(61%)
</td>
<td class="Botrule Rrule" align="center" valign="top">119<br>(52%)
</td>
<td class="Botrule Rrule" align="center" valign="top">114<br>(50%)
</td>
<td class="Botrule Rrule" align="center" valign="top">97<br>(45%)
</td>
<td class="Botrule Rrule" align="center" valign="top">99<br>(46%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Severe<br>(4)
</td>
<td class="Botrule Rrule" align="center" valign="top">69<br>(32%)
</td>
<td class="Botrule Rrule" align="center" valign="top">39<br>(18%)
</td>
<td class="Botrule Rrule" align="center" valign="top">51<br>(23%)
</td>
<td class="Botrule Rrule" align="center" valign="top">80<br>(38%)
</td>
<td class="Botrule Rrule" align="center" valign="top">36<br>(17%)
</td>
<td class="Botrule Rrule" align="center" valign="top">91<br>(41%)
</td>
<td class="Botrule Rrule" align="center" valign="top">36<br>(16%)
</td>
<td class="Botrule Rrule" align="center" valign="top">46<br>(21%)
</td>
<td class="Botrule Rrule" align="center" valign="top">86<br>(41%)
</td>
<td class="Botrule Rrule" align="center" valign="top">29<br>(14%)
</td>
<td class="Botrule Rrule" align="center" valign="top">81<br>(35%)
</td>
<td class="Botrule Rrule" align="center" valign="top">51<br>(22%)
</td>
<td class="Botrule Rrule" align="center" valign="top">61<br>(27%)
</td>
<td class="Botrule Rrule" align="center" valign="top">93<br>(44%)
</td>
<td class="Botrule Rrule" align="center" valign="top">47<br>(22%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Very Severe<br>(5)
</td>
<td class="Botrule Rrule" align="center" valign="top">8<br>(4%)
</td>
<td class="Botrule Rrule" align="center" valign="top">2<br>(0.9%)
</td>
<td class="Botrule Rrule" align="center" valign="top">4<br>(2%)
</td>
<td class="Botrule Rrule" align="center" valign="top">30<br>(14%)
</td>
<td class="Botrule Rrule" align="center" valign="top">15<br>(7%)
</td>
<td class="Botrule Rrule" align="center" valign="top">8<br>(4%)
</td>
<td class="Botrule Rrule" align="center" valign="top">1<br>(0.5%)
</td>
<td class="Botrule Rrule" align="center" valign="top">1<br>(0.5%)
</td>
<td class="Botrule Rrule" align="center" valign="top">29<br>(14%)
</td>
<td class="Botrule Rrule" align="center" valign="top">13<br>(6%)
</td>
<td class="Botrule Rrule" align="center" valign="top">9<br>(4%)
</td>
<td class="Botrule Rrule" align="center" valign="top">3<br>(1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">4<br>(2%)
</td>
<td class="Botrule Rrule" align="center" valign="top">24<br>(11%)
</td>
<td class="Botrule Rrule" align="center" valign="top">12<br>(6%)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">â€œClinical<br>Successâ€?
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">91<br>(42%*)
</td>
<td class="Botrule Rrule" align="center" valign="top">73<br>(33%*)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">85<br>(40%*)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">87<br>(39%*)
</td>
<td class="Botrule Rrule" align="center" valign="top">67<br>(30%*)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">107<br>(51%*)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">56<br>(24%)
</td>
<td class="Botrule Rrule" align="center" valign="top">50<br>(22%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">56<br>(26%)
</td>
</tr>
</tbody>
</table>
<p>At the end of 12 weeks of treatment, TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.05% and 0.1% was consistently superior to vehicle in reducing the plaque thickness of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>. Improvements in <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and scaling were generally significantly greater with TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.05% and 0.1% than with vehicle. TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.1% was also generally more effective than TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.05% in reducing the severity of the individual signs of disease. However, TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.1% was associated with a greater degree of local irritation than TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.05%.
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2. Mean Decreases in Plaque Elevation, Scaling and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span> in Two Controlled Clinical Trials for <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span>
</span></caption>
<col align="left" width="10.191%">
<col align="left" width="3.267%">
<col align="left" width="4.991%">
<col align="left" width="5.010%">
<col align="left" width="5.062%">
<col align="left" width="5.062%">
<col align="left" width="5.062%">
<col align="left" width="4.800%">
<col align="left" width="5.320%">
<col align="left" width="5.081%">
<col align="left" width="5.062%">
<col align="left" width="5.062%">
<col align="left" width="5.062%">
<col align="left" width="4.920%">
<col align="left" width="10%">
<col align="left" width="4.186%">
<col align="left" width="4.286%">
<col align="left" width="4.386%">
<col align="left" width="4.400%">
<col align="left" width="4.386%">
<col align="left" width="4.300%">
<tfoot>
<tr class="First"><td align="left" colspan="21" valign="top"><p class="First Footnote">Plaque elevation, scaling and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> scored on a 0-4 scale with 0=none, 1=mild, 2=moderate, 3=severe and 4=very severe.
</p></td></tr>
<tr><td align="left" colspan="21" valign="top"><p class="First Footnote">B#=Mean Baseline Severity;
</p></td></tr>
<tr><td align="left" colspan="21" valign="top"><p class="First Footnote">C-12=Mean Change from Baseline at end of 12 weeks of therapy;
</p></td></tr>
<tr><td align="left" colspan="21" valign="top"><p class="First Footnote">C-24=Mean Change from Baseline at week 24 (12 weeks after the end of therapy).
</p></td></tr>
<tr class="Last"><td align="left" colspan="21" valign="top"><p class="First Footnote"><span class="Bold">*Denotes statistically significant difference compared with vehicle.</span></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="6" valign="top">
<span class="Bold">TAZORAC</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">Cream, 0.05%</span>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="6" valign="top">
<span class="Bold">TAZORAC</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">Cream, 0.1%</span>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="7" valign="top"><span class="Bold">Vehicle Cream</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top">
<br>Lesion<br>
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Trunk/Arm/<br>Leg lesions
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Knee/Elbow<br>lesions
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">All Treated
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Trunk/Arm/<br>Leg lesions
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Knee/Elbow<br>lesions
</td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">All Treated
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Trunk/Arm/<br>Leg lesions
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Knee/Elbow<br>lesions
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">All Treated
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" colspan="2" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">Trial 1
</td>
<td class="Botrule Rrule" align="center" valign="top">Trial 2
</td>
<td class="Botrule Rrule" align="center" valign="top">Trial 1
</td>
<td class="Botrule Rrule" align="center" valign="top">Trial 2
</td>
<td class="Botrule Rrule" align="center" valign="top">Trial 1
</td>
<td class="Botrule Rrule" align="center" valign="top">Trial 2
</td>
<td class="Botrule Rrule" align="center" valign="top">Trial 1
</td>
<td class="Botrule Rrule" align="center" valign="top">Trial 2
</td>
<td class="Botrule Rrule" align="center" valign="top">Trial 1
</td>
<td class="Botrule Rrule" align="center" valign="top">Trial 2
</td>
<td class="Botrule Rrule" align="center" valign="top">Trial 1
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Trial 2
</td>
<td class="Botrule Rrule" align="center" valign="top">Trial 1
</td>
<td class="Botrule Rrule" align="center" valign="top">Trial 2
</td>
<td class="Botrule Rrule" align="center" valign="top">Trial 1
</td>
<td class="Botrule Rrule" align="center" valign="top">Trial 2
</td>
<td class="Botrule Rrule" align="center" valign="top">Trial 1
</td>
<td class="Botrule Rrule" align="center" valign="top">Trial 2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">N=218
</td>
<td class="Botrule Rrule" align="center" valign="top">N=210
</td>
<td class="Botrule Rrule" align="center" valign="top">N=218
</td>
<td class="Botrule Rrule" align="center" valign="top">N=210
</td>
<td class="Botrule Rrule" align="center" valign="top">N=218
</td>
<td class="Botrule Rrule" align="center" valign="top">N=210
</td>
<td class="Botrule Rrule" align="center" valign="top">N=221
</td>
<td class="Botrule Rrule" align="center" valign="top">N=211
</td>
<td class="Botrule Rrule" align="center" valign="top">N=221
</td>
<td class="Botrule Rrule" align="center" valign="top">N=211
</td>
<td class="Botrule Rrule" align="center" valign="top">N=221
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">N=211
</td>
<td class="Botrule Rrule" align="center" valign="top">N=229
</td>
<td class="Botrule Rrule" align="center" valign="top">N=214
</td>
<td class="Botrule Rrule" align="center" valign="top">N=229
</td>
<td class="Botrule Rrule" align="center" valign="top">N=214
</td>
<td class="Botrule Rrule" align="center" valign="top">N=229
</td>
<td class="Botrule Rrule" align="center" valign="top">N=214
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Plaque<br>elevation
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">B#</span><br>C-12<br>C-24
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.29</span><br>-0.83*<br>-0.75*
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.50</span><br>-0.98*<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.40</span><br>-0.91*<br>-0.73*
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.52</span><br>-1.04*<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.28</span><br>-0.75*<br>-0.60*
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.51</span><br>-0.90*<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.34</span><br>-1.08*<br>-0.87*
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.52</span><br>-1.25*<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.35</span><br>-0.96*<br>-0.73*
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.49</span><br>-1.21*<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.32</span><br>-0.83*<br>-0.63*
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">
<span class="Bold Underline">2.51</span><br>-1.08*<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.28</span><br>-0.59<br>-0.57
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.51</span><br>-0.69<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.35</span><br>-0.57<br>-0.49
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.51</span><br>-0.68<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.29</span><br>-0.48<br>-0.42
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.51</span><br>-0.61<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Scaling
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">B#</span><br>C-12<br>C-24
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.26</span><br>-0.75<br>-0.68
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.45</span><br>-0.90<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.47</span><br>-0.78*<br>-0.62*
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.60</span><br>-0.98*<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.32</span><br>-0.67*<br>-0.51*
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.47</span><br>-0.80<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.37</span><br>-0.84*<br>-0.79*
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.45</span><br>-1.06*<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.40</span><br>-0.76*<br>-0.61*
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.57</span><br>-1.13*<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.36</span><br>-0.73*<br>-0.59*
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">
<span class="Bold Underline">2.53</span><br>-1.03*<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.34</span><br>-0.66<br>-0.56
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.46</span><br>-0.79<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.45</span><br>-0.62<br>-0.45
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.61</span><br>-0.76<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.31</span><br>-0.46<br>-0.34
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.53</span><br>-0.70<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">B#</span><br>C-12<br>C-24
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.26</span><br>-0.49<br>-0.52
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.51</span><br>-0.65*<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.17</span><br>-0.44<br>-0.44
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.40</span><br>-0.66*<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.23</span><br>-0.40<br>-0.41
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.48</span><br>-0.62<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.25</span><br>-0.49<br>-0.55
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.53</span><br>-0.82*<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.17</span><br>-0.57*<br>-0.52*
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.42</span><br>-0.82*<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.21</span><br>-0.42*<br>-0.39*
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">
<span class="Bold Underline">2.51</span><br>-0.78*<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.24</span><br>-0.42<br>-0.43
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.47</span><br>-0.46<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.17</span><br>-0.38<br>-0.34
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.34</span><br>-0.44<br>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.24</span><br>-0.37<br>-0.33
</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold Underline">2.47</span><br>-0.47<br>
</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-13.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>:</span></p>
<p>In two large vehicle-controlled trials, subjects age 12 years and over with facial <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> of a severity suitable for monotherapy with a topical agent were enrolled. After face cleansing in the evening, TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.1% was applied once daily to the entire face as a thin layer. TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream, 0.1% was significantly more effective than vehicle in the treatment of facial <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>. Efficacy results after 12 weeks of treatment are shown in <a href="#t3">Table 3</a>:
</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3. Efficacy Results after Twelve Weeks of Treatment in Two Controlled Clinical Trials for <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>
</span></caption>
<col align="left" width="57.189%">
<col align="left" width="12.777%">
<col align="left" width="12.877%">
<col align="left" width="8.578%">
<col align="left" width="8.578%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Bold">*Denotes statistically significant difference compared with vehicle.</span></p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">TAZORAC</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">Cream, 0.1%</span>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Vehicle Cream</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Trial 1</span><br>N=218
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Trial 2</span> N=206
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Trial 1</span><br>N=218
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Trial 2</span><br>N=205
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Median Percent Reduction in
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><ul class="Disc"><li>Noninflammatory lesions
</li></ul></td>
<td class="Rrule" align="center" valign="top">46%*
</td>
<td class="Rrule" align="center" valign="top">41%*
</td>
<td class="Rrule" align="center" valign="top">27%
</td>
<td class="Rrule" align="center" valign="top">21%
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><ul class="Disc"><li>Inflammatory lesions
</li></ul></td>
<td class="Rrule" align="center" valign="top">41%*
</td>
<td class="Rrule" align="center" valign="top">44%*
</td>
<td class="Rrule" align="center" valign="top">27%
</td>
<td class="Rrule" align="center" valign="top">25%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><ul class="Disc"><li>Total lesions
</li></ul></td>
<td class="Botrule Rrule" align="center" valign="top">44%*
</td>
<td class="Botrule Rrule" align="center" valign="top">42%*
</td>
<td class="Botrule Rrule" align="center" valign="top">24%
</td>
<td class="Botrule Rrule" align="center" valign="top">21%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Percent of Subjects with No <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span> or Minimal <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">18%*
</td>
<td class="Botrule Rrule" align="center" valign="top">20%*
</td>
<td class="Botrule Rrule" align="center" valign="top">11%
</td>
<td class="Botrule Rrule" align="center" valign="top">6%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Percent of Subjects with No <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, Minimal <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, or Mild <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">55%*<br>
</td>
<td class="Botrule Rrule" align="center" valign="top">53%*<br>
</td>
<td class="Botrule Rrule" align="center" valign="top">36%<br>
</td>
<td class="Botrule Rrule" align="center" valign="top">36%<br>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s38"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">TAZORAC<span class="Sup">Â®</span> Cream is a white cream available in concentrations of 0.05% and 0.1%. It is supplied in a collapsible aluminum tube with a tamper-evident aluminum membrane over the opening and a white polypropylene screw cap, in 30 g and 60 g sizes.
</p>
<table width="100%">
<col align="left" width="18.700%">
<col align="left" width="37.067%">
<col align="left" width="44.233%">
<tbody class="Headless">
<tr class="First"><td align="center" colspan="3" valign="top">TAZORAC<span class="Sup">Â®</span> Cream, 0.05%   TAZORAC<span class="Sup">Â®</span> Cream, 0.1%
</td></tr>
<tr>
<td align="center" valign="top">30 g
</td>
<td align="center" valign="top">NDC 0023-9155-30
</td>
<td align="center" valign="top">NDC 0023-9156-30
</td>
</tr>
<tr class="Last">
<td align="center" valign="top">60 g
</td>
<td align="center" valign="top">NDC 0023-9155-60
</td>
<td align="center" valign="top">NDC 0023-9156-60
</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="s39"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Italics">Storage:</span> Store at 20Â°C to 25Â°C (68Â°F to 77Â°F). Excursions permitted from -5Â°C to 30Â°C (23Â°F to 86Â°F).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s40"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Patient Information).
</p>
<p>Advise the patient of the following:
</p>
<ul class="Disc">
<li>Fetal risk associated with TAZORAC<span class="Sup">Â®</span> Cream for females of childbearing potential. Advise patients to use an effective method of contraception during treatment to avoid pregnancy. Advise the patient to stop medication if she becomes pregnant and call her doctor [<span class="Italics">see Contraindications (<a href="#s9">4.1</a>), Warnings and Precautions (<a href="#s12">5.1</a>) and Use in Specific Populations (<a href="#s21">8.1</a>)</span>].
</li>
<li>For the patient with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, apply TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream only to <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesions</span>, avoiding uninvolved skin.
</li>
<li>If undue irritation (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>) occurs, reduce frequency of application or temporarily interrupt treatment. Treatment may be resumed once irritation subsides [s<span class="Italics">ee Dosage and Adminstration (<a href="#s5">2.1</a>)</span>].
</li>
<li>Moisturizers may be used as frequently as desired.
</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> may use a cream or lotion to soften or moisten skin at least 1 hour before applying TAZORAC<span class="Sup">Â®</span> Cream.
</li>
<li>Avoid exposure of the treated areas to either natural or artificial sunlight, including tanning beds and sun lamps. Use sunscreen and protective clothing if exposure to sunlight is unavoidable when using TAZORAC<span class="Bold"><span class="Sup">Â®</span></span> Cream.
</li>
<li>Avoid contact with the eyes. If TAZORAC<span class="Sup">Â®</span> Cream gets in or near their eyes, rinse thoroughly with water.
</li>
<li>Not for ophthalmic, oral, or intravaginal use.
</li>
<li>Wash their hands after applying TAZORAC<span class="Sup">Â®</span> Cream.
</li>
</ul>
<p>Manufactured by: Allergan, Inc., Irvine, CA 92612, U.S.A.
</p>
<p>Â© 2014 Allergan, Inc.<br>Â® marks owned by Allergan, Inc. <br>Made in the U.S.A.
</p>
<p>--------------------Cut Hereâœ‚----------------------------------------------------------------------------------------------------
</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="s41"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">TAZORAC</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">(TAZ-or-ac)</span></p>
<p>(tazarotene)
</p>
<p>Cream
</p>
<table width="100%">
<col align="left" width="100.000%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Important information: TAZORAC<span class="Sup">Â®</span> Cream is for use on skin only. Do not use TAZORAC<span class="Sup">Â®</span> Cream in your eyes, mouth, or vagina.
</td></tr></tbody>
</table>
<p><a name="p01"></a><span class="Bold">What is the most important information I should know about TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">Cream?</span></p>
<p><span class="Bold">TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">Cream may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> if used during pregnancy.</span></p>
<ul class="Disc">
<li>
<span class="Bold">Females must not be pregnant when they start using TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">Cream or become pregnant during treatment with TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">Cream.</span>
</li>
<li>For females who are able to get pregnant:<ul class="Circle">
<li>Your doctor should order a pregnancy test for you within 2 weeks before you begin treatment with TAZORAC<span class="Sup">Â®</span> Cream to be sure that you are not pregnant. Your doctor will decide when to do the test.
</li>
<li>You should begin treatment with TAZORAC<span class="Sup">Â®</span> Cream during a normal menstrual period.
</li>
<li>Use an effective form of birth control during treatment with TAZORAC<span class="Sup">Â®</span> Cream.  Talk with your doctor about birth control options that may be used to prevent pregnancy during treatment with TAZORAC<span class="Sup">Â®</span> Cream.
</li>
<li>
<span class="Bold">Stop using TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">Cream and tell your doctor right away if you become pregnant while using TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">Cream.</span>
</li>
</ul>
</li>
</ul>
<p><span class="Bold">What is TAZORAC</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">Cream?</span></p>
<ul class="Disc">
<li>TAZORAC<span class="Sup">Â®</span> Cream 0.05% and 0.1% is a prescription medicine used on the skin (topical) to treat people with plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>.
</li>
<li>TAZORAC<span class="Sup">Â®</span> Cream 0.1% is also used on the skin to treat people with <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>.
</li>
</ul>
<p>It is not known if TAZORAC<span class="Sup">Â®</span> Cream is safe and effective for treating <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> in children under 18 years of age, or for treating <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> in children under 12 years of age.
</p>
<p><span class="Bold">Who should not use TAZORAC</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">Cream?</span></p>
<p><span class="Bold">Do not use TAZORAC</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">Cream if you:</span></p>
<ul class="Disc">
<li>
<span class="Bold">are pregnant, or you are able to become pregnant and are not using effective birth control</span>. See the section called â€œ<a href="#p01">What is the most important information I should know about TAZORAC</a><span class="Sup">Â®</span><a href="#p01"> Cream?</a>â€? at the beginning of this leaflet.
</li>
<li>are allergic to any of the ingredients in TAZORAC<span class="Sup">Â®</span> Cream. See the end of this leaflet for a complete list of ingredients in TAZORAC<span class="Sup">Â®</span> Cream.
</li>
</ul>
<p><span class="Bold">What should I tell my doctor before using TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">Cream?</span></p>
<p><span class="Bold">Before you use TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">Cream, tell your doctor if you:</span></p>
<ul class="Disc">
<li>have <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span> or any other skin problems
</li>
<li>have any other medical conditions
</li>
<li>are breastfeeding or plan to breastfeed. It is not known if TAZORAC<span class="Sup">Â®</span> Cream passes into your breast milk. You and your doctor should decide if you will use TAZORAC<span class="Sup">Â®</span> Cream or breastfeed. You should not do both.
</li>
</ul>
<p>Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. <span class="Bold">Certain medicines, vitamins, or supplements may make your skin more sensitive to sunlight</span>. Also, tell your doctor about any cosmetics you use, including moisturizers, creams, lotions, or products that can dry out your skin.
</p>
<p><span class="Bold">How should I use TAZORAC</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">Cream?</span></p>
<ul class="Disc">
<li>Use TAZORAC<span class="Sup">Â®</span> Cream exactly as your doctor tells you to use it.
</li>
<li>
<span class="Bold">If you have <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span></span>:<ul class="Disc">
<li>If you shower or bathe before applying TAZORAC<span class="Sup">Â®</span> Cream, your skin should be dry before applying the cream.
</li>
<li>You may use a cream or lotion to soften or moisten your skin at least 1 hour before you apply TAZORAC<span class="Sup">Â®</span> Cream.
</li>
<li>Apply a thin layer of TAZORAC<span class="Sup">Â®</span> Cream to cover only the <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> lesions, 1 time each day, in the evening.
</li>
</ul>
</li>
<li>
<span class="Bold">If you have <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span></span>:<ul class="Disc">
<li>Gently wash and dry your face before applying TAZORAC<span class="Sup">Â®</span> Cream.
</li>
<li>Apply a thin layer of TAZORAC<span class="Sup">Â®</span> Cream to cover all of the affected skin areas, 1 time each day, in the evening.
</li>
</ul>
</li>
<li>TAZORAC<span class="Sup">Â®</span> Cream should not be applied to unaffected skin. TAZORAC<span class="Sup">Â®</span> Cream may cause irritation to unaffected skin.
</li>
<li>TAZORAC<span class="Sup">Â®</span> Cream should not be used on skin with <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span> because it may cause severe irritation.
</li>
<li>Do not get TAZORAC<span class="Sup">Â®</span> Cream in your eyes, on your eyelids, or in your mouth. If TAZORAC<span class="Sup">Â®</span> Cream gets in or near your eyes, rinse them well with water.
</li>
<li>Wash your hands after applying TAZORAC<span class="Sup">Â®</span> Cream.
</li>
<li>If you swallow TAZORAC<span class="Sup">Â®</span> Cream, call your doctor or go to the nearest hospital emergency room right away.
</li>
</ul>
<p><span class="Bold">What should I avoid while using TAZORAC</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">Cream?</span></p>
<ul class="Disc"><li>Avoid sunlight, including sunlamps, as much as possible. TAZORAC<span class="Sup">Â®</span> Cream can make your skin more sensitive to the sun, and the light from sunlamps and tanning beds. You could get a severe sunburn. Use sunscreen with at least SPF 15, and wear a hat and clothes that cover your skin if you have to be in sunlight.  <br>Talk to your doctor if you get a sunburn during treatment with TAZORAC<span class="Sup">Â®</span> Cream. If you get a sunburn, do not use TAZORAC<span class="Sup">Â®</span> Cream until your sunburn is healed.
</li></ul>
<p><span class="Bold">What are the possible side effects of TAZORAC</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">Cream?</span></p>
<p><span class="Bold">TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">Cream may cause serious side effects, including:</span></p>
<ul class="Disc"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">Skin irritation</span>.</span> TAZORAC<span class="Sup">Â®</span> Cream may cause <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, and <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of your skin. Also, <span class="product-label-link" type="condition" conceptid="4221803" conceptname="Flatus">wind</span> or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> weather may be more irritating to your skin while you are using TAZORAC<span class="Sup">Â®</span> Cream. Tell your doctor if you develop any of these symptoms of <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span> with TAZORAC<span class="Sup">Â®</span> Cream. Your doctor may tell you to stop using TAZORAC<span class="Sup">Â®</span> Cream until your skin heals, change your dose of TAZORAC<span class="Sup">Â®</span> Cream, or your doctor may tell you to use it less often, if you get too much <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>.
</li></ul>
<p><span class="Bold">The most common side effects of TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">Cream in people with plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> include:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>
</li>
<li>burning
</li>
</ul>
<p><span class="Bold">The most common side effects of TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">Cream in people with <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> include:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>
</li>
<li>burning
</li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.
</p>
<p>These are not all the possible side effects of TAZORAC<span class="Sup">Â®</span> Cream. For more information, ask your doctor or pharmacist.
</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
</p>
<p><span class="Bold">How should I store TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">Cream?</span></p>
<ul class="Disc"><li>Store TAZORAC<span class="Sup">Â®</span> Cream at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).
</li></ul>
<p><span class="Bold">Keep TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">Cream and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">Cream.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TAZORAC<span class="Sup">Â®</span> Cream for a condition for which it was not prescribed. Do not give TAZORAC<span class="Sup">Â®</span> Cream to other people, even if they have the same symptoms you have. It may harm them.
</p>
<p>If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about TAZORAC<span class="Sup">Â®</span> Cream that is written for health professionals.
</p>
<p>For more information call 1-800-433-8871 or go to www.tazorac.com.
</p>
<p><span class="Bold">What are the ingredients in TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">Cream?</span></p>
<p><span class="Bold">Active ingredient:</span> tazarotene
</p>
<p><span class="Bold">Inactive ingredients:</span> benzyl alcohol 1%, Carbomer 1342, carbomer homopolymer type B, edetate disodium, medium chain triglycerides, mineral oil, purified water, sodium hydroxide, sodium thiosulfate, and sorbitan monooleate
</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.
</p>
<p>Revised: December 2013
</p>
<p>Manufactured by: Allergan, Inc., Irvine, CA 92612, U.S.A.
</p>
<p>Â© 2014 Allergan, Inc.<br>Â® marks owned by Allergan, Inc. <br>Made in the U.S.A.
</p>
<p><a name="f02"></a><img alt="Logo
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd02ea43-7668-4872-a655-ee31c456e345&amp;name=allerganlogo.jpg"></p>
<p>72709US10
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s42"></a><a name="section-17"></a><p></p>
<p class="First">
							NDC 0023-9155-60Â  Â  Â  Â  Â  <span class="Bold">Rx only</span></p>
<p><span class="Bold">60 grams</span></p>
<p><span class="Bold">TAZORAC</span><span class="Sup">Â®</span><br><span class="Bold">(TAZAROTENE)</span><br><span class="Bold Italics">cream, 0.05%</span></p>
<p><span class="Bold">For Topical Use Only</span><br><span class="Bold">Not for Ophthalmic Use</span></p>
<p><span class="Bold">ALLERGAN
</span><span class="Sup">Â®</span></p>
<div class="Figure">
<a name="f03"></a><img alt="PRINCIPAL DISPLAY PANEL
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd02ea43-7668-4872-a655-ee31c456e345&amp;name=carton1.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s43"></a><a name="section-18"></a><p></p>
<p class="First">
							NDC 0023-9156-60Â  Â  Â  Â  Â  <span class="Bold">Rx only</span></p>
<p><span class="Bold">60 grams</span></p>
<p><span class="Bold">TAZORAC</span><span class="Sup">Â®</span><br><span class="Bold">(TAZAROTENE)</span><br><span class="Bold Italics">cream, 0.1%</span></p>
<p><span class="Bold">For Topical Use Only</span><br><span class="Bold">Not for Ophthalmic Use</span></p>
<p><span class="Bold">ALLERGAN
</span><span class="Sup">Â®</span></p>
<div class="Figure">
<a name="f04"></a><img alt="PRINCIPAL DISPLAY PANEL
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd02ea43-7668-4872-a655-ee31c456e345&amp;name=carton2.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TAZORAC
Â 		
					</strong><br><span class="contentTableReg">tazarotene cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0023-9155</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">CUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>tazarotene
</strong> (tazarotene) </td>
<td class="formItem">tazarotene
</td>
<td class="formItem">0.5Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Benzyl alcohol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARBOMER HOMOPOLYMER TYPE B</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carbomer 1342</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CAPRYLIC/CAPRIC MONO/DIGLYCERIDES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mineral oil</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium thiosulfate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sorbitan monooleate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0023-9155-30</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0023-9155-60</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">60 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0023-9155-15</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">3.5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021184</td>
<td class="formItem">11/15/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TAZORAC
Â 		
					</strong><br><span class="contentTableReg">tazarotene cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0023-9156</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">CUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>tazarotene
</strong> (tazarotene) </td>
<td class="formItem">tazarotene
</td>
<td class="formItem">1Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Benzyl alcohol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARBOMER HOMOPOLYMER TYPE B</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carbomer 1342</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CAPRYLIC/CAPRIC MONO/DIGLYCERIDES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mineral oil</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium thiosulfate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sorbitan monooleate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0023-9156-30</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0023-9156-60</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">60 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0023-9156-15</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">3.5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021184</td>
<td class="formItem">11/13/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Allergan, Inc.

							(144796497)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Allergan, Inc.</td>
<td class="formItem"></td>
<td class="formItem">362898611</td>
<td class="formItem">MANUFACTURE(0023-9155, 0023-9156)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f00dc25e-c69b-4685-bdd0-48d8fd634ce3</div>
<div>Set id: dd02ea43-7668-4872-a655-ee31c456e345</div>
<div>Version: 6</div>
<div>Effective Time: 20131220</div>
</div>
</div>Â <div class="DistributorName">Allergan, Inc.
</div></p>
</body></html>
